Elevated levels of circulating CXCL4 + CCL20 + CXCL1 in combination can discriminate among ovarian cancer patients those who are predisposed to shorter progression-free survival and overall survival [42,43]. This evidence concerns the gene PF4 and ovarian carcinoma.